Debate: Should MRD Monitoring in AML Be Routine? Pro

Initial formal criteria, based on microscopic evaluation of the bone marrow and blood as well as patient examination, to define treatment responses such as “complete remission” (CR) in acute myeloid leukemia (AML) were proposed over 60 years ago. These criteria have remained essentially unchanged over time and continue to serve as standard for response assessment, as surrogate endpoint in early-phase clinical trials, and as basis for clinical decis ion-making. Because relapse from morphologic CR is common, however, much effort has focused over the last 40 years on strategies to detect submicroscopic, “minimal” (or, perhaps more appropriately, “measurable”) residual disease (MRD), paralleling efforts in other disease such as chronic mye loid leukemia (CML).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research